CN105637367A - 胰腺癌相关材料和方法 - Google Patents

胰腺癌相关材料和方法 Download PDF

Info

Publication number
CN105637367A
CN105637367A CN201480056359.9A CN201480056359A CN105637367A CN 105637367 A CN105637367 A CN 105637367A CN 201480056359 A CN201480056359 A CN 201480056359A CN 105637367 A CN105637367 A CN 105637367A
Authority
CN
China
Prior art keywords
tumor
protein
pancreatic
proteins
phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480056359.9A
Other languages
English (en)
Chinese (zh)
Inventor
Z·尤
N·希顿
A·夸利亚
D·布里顿
M·沃德
I·派克
V·米特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
King's College Hospital NHS Foundation Trust
Original Assignee
Electrophoretics Ltd
King's College Hospital NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd, King's College Hospital NHS Foundation Trust filed Critical Electrophoretics Ltd
Publication of CN105637367A publication Critical patent/CN105637367A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201480056359.9A 2013-08-13 2014-08-13 胰腺癌相关材料和方法 Pending CN105637367A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1314485.2 2013-08-13
GBGB1314485.2A GB201314485D0 (en) 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer
PCT/GB2014/052475 WO2015022530A2 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer

Publications (1)

Publication Number Publication Date
CN105637367A true CN105637367A (zh) 2016-06-01

Family

ID=49262110

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480056359.9A Pending CN105637367A (zh) 2013-08-13 2014-08-13 胰腺癌相关材料和方法

Country Status (7)

Country Link
US (1) US20160195536A1 (cg-RX-API-DMAC10.html)
EP (1) EP3033624A2 (cg-RX-API-DMAC10.html)
JP (1) JP2016535270A (cg-RX-API-DMAC10.html)
CN (1) CN105637367A (cg-RX-API-DMAC10.html)
CA (1) CA2920946A1 (cg-RX-API-DMAC10.html)
GB (1) GB201314485D0 (cg-RX-API-DMAC10.html)
WO (1) WO2015022530A2 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
CN112585470A (zh) * 2018-06-21 2021-03-30 乌得勒支大学控股有限责任公司 用于监测样品中激酶活性的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
KR20190111932A (ko) * 2016-12-20 2019-10-02 트리트포라이프 에이비 질량 분석법에 의해서 braf 돌연변이 및 야생형 braf 단백질을 결정하는 방법
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
JP7866750B2 (ja) * 2021-01-14 2026-05-28 公立大学法人福島県立医科大学 がんの予後バイオマーカー

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
AU2002323139A1 (en) 2001-08-14 2003-03-03 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
DE102006056784A1 (de) * 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival
JP2012516445A (ja) * 2009-01-27 2012-07-19 ホロジック，インコーポレイテッド 体液における新生児敗血症の検出のためのバイオマーカー
US20130023436A1 (en) * 2010-01-15 2013-01-24 Bryan William Jones Disease diagnosis and treatment using computational molecular phenotyping
TW201130830A (en) * 2010-02-01 2011-09-16 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AU2011242990B2 (en) * 2010-04-19 2015-02-12 Biomarker Strategies, Llc. Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
CN108872579A (zh) * 2010-06-01 2018-11-23 梅坦诺米克斯保健有限公司 用于在受试者中诊断胰腺癌的工具和方法
CN103068851B (zh) * 2010-06-16 2015-03-11 高等教育联邦系统-匹兹堡大学 内质蛋白的抗体及其用途
AU2012267888A1 (en) * 2011-06-07 2014-01-30 Caris Mpi, Inc. Molecular profiling for cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID BRITTON ET AL.: "Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets", 《PLOS ONE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
CN112585470A (zh) * 2018-06-21 2021-03-30 乌得勒支大学控股有限责任公司 用于监测样品中激酶活性的方法

Also Published As

Publication number Publication date
WO2015022530A3 (en) 2015-04-09
WO2015022530A2 (en) 2015-02-19
JP2016535270A (ja) 2016-11-10
EP3033624A2 (en) 2016-06-22
US20160195536A1 (en) 2016-07-07
CA2920946A1 (en) 2015-02-19
GB201314485D0 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
Lucarelli et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml
Schrödter et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma
Mikula et al. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors
Maes et al. Proteomics in cancer research: Are we ready for clinical practice?
Hadisurya et al. Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson’s disease
US20160195536A1 (en) Materials and Methods Relating to Pancreatic Cancer
Ghosh et al. A cell-surface membrane protein signature for glioblastoma
Com et al. Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma
Gajbhiye et al. Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics
US20240084394A1 (en) Urinary metabolomic biomarkers for detecting colorectal cancer and polyps
Vellaichamy et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases
HK1248316A1 (en) Methods of assessing colorectal health of an individual
Duangkumpha et al. Discovery and qualification of serum protein biomarker candidates for cholangiocarcinoma diagnosis
Jiang et al. iTRAQ‐based quantitative proteomics approach identifies novel diagnostic biomarkers that were essential for glutamine metabolism and redox homeostasis for gastric cancer
GB2551415A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
Pavlou et al. Coupling proteomics and transcriptomics in the quest of subtype‐specific proteins in breast cancer
Nie et al. Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method
Wu et al. Next-generation novel noninvasive cancer molecular diagnostics platforms beyond tissues
US20260092922A1 (en) Markers for the diagnosis of biochemical recurrence in prostate cancer
CN110121647A (zh) 用于检测和治疗胰腺导管腺癌的方法
Chinello et al. The proteomic landscape of renal tumors
Sun et al. From clinic to mechanism: Proteomics‐based assessment of angiogenesis in adrenal pheochromocytoma
Liu et al. Dysregulation of phosphoproteins in hepatocellular carcinoma revealed via quantitative analysis of the phosphoproteome
Zhang et al. The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer
CA3065979A1 (en) Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: London, England

Applicant after: Electrophoretics Limited

Applicant after: KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST

Address before: surrey

Applicant before: Electrophoretics Limited

Applicant before: KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20160601

RJ01 Rejection of invention patent application after publication